Iovance Biotherapeutics Inc to Discuss SITC Clinical Data Updates Transcript
Good day, thank you for standing by, and welcome to the Iovance SITC Update Call. (Operator Instructions)
I would now like to turn the conference over to your host, Ms. Sara Pellegrino, Vice President, Investor and Public Relations of Iovance Biotherapeutics. Please go ahead, ma'am.
Thank you, operator. Good afternoon, and thank you for joining our conference call to discuss the clinical data updates for Iovance TIL cell therapy in multiple solid tumors during SITC 2021. For today's agenda, our Interim President and CEO, Fred Vogt will do a brief introduction; Dr. Friedrich Finckenstein, our Chief Medical Officer, will highlight the key takeaways for each data set in relation to our TIL development strategy. The highlight of today's call will be clinical data updates for Iovance TIL in metastatic non-small cell lung cancer and Iovance TIL in combination with pembrolizumab in early-line cervical cancer, melanoma and head and neck cancer.
We are fortunate to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |